Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer.

Autor: Franco-Mateos, Emma1 (AUTHOR) emmafranco00@gamil.com, Souza-Egipsy, Virginia1 (AUTHOR) virginia.souza-egipsy@csic.es, García-Estévez, Laura2 (AUTHOR) lgestevez@mdanderson.es, Pérez-García, José3,4,5 (AUTHOR) josemanuel.perez@ibcc.clinic, Gion, María6 (AUTHOR) mariagion@gmail.com, Garrigós, Laia3 (AUTHOR) laia.garrigos@ibcc.clinic, Cortez, Patricia7 (AUTHOR) patricia.cortez@iobmadrid.com, Saavedra, Cristina6 (AUTHOR) cristina.saavedra@iobmadrid.com, Gómez, Patricia3 (AUTHOR) patricia.gomez@ibcc.clinic, Ortiz, Carolina3 (AUTHOR) carolina.ortiz@ibcc.clinic, Cruz, Víctor L.1 (AUTHOR) vl.cruz@csic.es, Ramos, Javier1 (AUTHOR) j.ramos@csic.es, Cortés, Javier3,4,8 (AUTHOR) javier.cortes@maj3.health, Vega, Juan F.1 (AUTHOR) jf.vega@csic.es
Zdroj: International Journal of Molecular Sciences. Apr2024, Vol. 25 Issue 7, p3940. 14p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje